Herpes zoster vaccine (Zostavax) for the prevention of herpes zoster and herpes zoster-related post-herpetic neuralgia

The WAR reached the follow conclusions:
Zostavax has an added therapeutic value in comparison with placebo for the prevention of herpes zoster (HZ) and herpes zoster-related post-herpetic neuralgia (PHN) in immunocompetent adults aged 70 years or older.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.